Shares of Forty Seven Inc (NASDAQ:FTSV) saw unusually-high trading volume on Friday . Approximately 937,719 shares traded hands during mid-day trading, an increase of 740% from the previous session’s volume of 111,665 shares.The stock last traded at $13.23 and had previously closed at $12.87.

FTSV has been the subject of several research analyst reports. Canaccord Genuity initiated coverage on shares of Forty Seven in a research note on Monday, July 23rd. They issued a “buy” rating and a $22.00 price objective for the company. Morgan Stanley initiated coverage on shares of Forty Seven in a research note on Monday, July 23rd. They issued an “overweight” rating and a $25.00 price objective for the company. Credit Suisse Group initiated coverage on shares of Forty Seven in a research note on Monday, July 23rd. They issued an “outperform” rating and a $24.00 price objective for the company. Finally, Oppenheimer initiated coverage on shares of Forty Seven in a research note on Monday, July 23rd. They issued an “outperform” rating and a $35.00 price objective for the company.

Forty Seven (NASDAQ:FTSV) last released its quarterly earnings data on Monday, August 13th. The company reported ($2.52) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($1.84). research analysts forecast that Forty Seven Inc will post -2.96 earnings per share for the current year.

In other Forty Seven news, insider Stefan A. Dyckerhoff purchased 136,650 shares of the firm’s stock in a transaction on Monday, July 2nd. The stock was acquired at an average price of $16.00 per share, for a total transaction of $2,186,400.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christopher J. Schaepe purchased 468,750 shares of the firm’s stock in a transaction on Monday, July 2nd. The shares were acquired at an average price of $16.00 per share, with a total value of $7,500,000.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,106,300 shares of company stock valued at $17,427,395 in the last 90 days.

A number of hedge funds have recently made changes to their positions in FTSV. TD Asset Management Inc. bought a new stake in Forty Seven during the 2nd quarter valued at $215,000. Dean Capital Investments Management LLC bought a new stake in Forty Seven during the 2nd quarter valued at $638,000. Board of Trustees of The Leland Stanford Junior University bought a new stake in Forty Seven during the 2nd quarter valued at $11,252,000. BlackRock Inc. bought a new stake in Forty Seven during the 2nd quarter valued at $548,000. Finally, Janus Henderson Group PLC bought a new stake in Forty Seven during the 2nd quarter valued at $160,000. Institutional investors and hedge funds own 41.05% of the company’s stock.

Forty Seven Company Profile (NASDAQ:FTSV)

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.

See Also: Intrinsic Value and Stock Selection

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.